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Background: This Dutch travel Vaccination Study (DiVeST) aimed to study adherence or compliance to Dutch
travel health guidelines in travelling families and to identify risk groups to provide better advice and protection
for international travellers.
Methods: Between 2016 and 2018, family members who travelled to Eastern Europe or outside Europe during
the preceding year were recruited via Dutch secondary schools. The vaccination status of the travellers was
assessed using questionnaires and vaccination records and hepatitis A virus antibody concentrations in dried
blood spot (DBS) eluates. Subgroups of travellers with lower adherence to guidelines were identiﬁed.
Results: Of the 246 travellers that participated in this study, 155 (63%) travelled to destinations for which the
HAV vaccination was recommended. Of these 155 travellers, 56 (36%) said they visited a pre-travel clinic, and
64 of them (41%) showed a valid HAV vaccination in their vaccination records. Of the 145 travellers with
available DBS eluates, anti-HAV antibodies were detected in 98 (68%) of them.
Conclusions: We found that adherence to travel health guidelines, in terms of HAV vaccination, was suboptimal.
According to our results, speciﬁc attention should be paid to children, persons visiting friends and relatives and
those who travel relatively short distances.
1. Introduction
The dynamic ﬁeld of travel medicine has undergone some serious
changes during the past 10 years. Currently, in many Western European
countries, the total number of people travelling internationally is equal
to, or even exceeds, the respective number of inhabitants in those
countries [1]. And not only has the number of travellers increased, the
distance that these people travel has also increased signiﬁcantly. Re-
mote areas are becoming more accessible, while ﬂights are becoming
more and more aﬀordable. Nowadays, the accessibility of air traﬃc
makes it possible to travel to the other side of the world in a matter of
hours. A few decades ago this would have taken several days [2]. The
growing number of people able to travel now goes hand-in-hand with
an increased exposure to infectious diseases. Furthermore, the ease of
international travel and the wide availability of “last-minute” trips
nowadays can make people unaware of the necessity to take pre-travel
precautions.
Travellers are increasingly at risk of exposure to pathogens that they
have never encountered before. The risk of infection varies greatly per
country and so can the appropriate preventive measurements re-
commended before travelling. International travel health guidelines are
available and the vaccinations recommended will depend on travellers’
health, risk behaviour, length of stay, and, most importantly, travel
destination. Furthermore, recommendations may diﬀer between var-
ious international guidelines, reﬂecting diﬀerences of risk assessments
between countries, vaccination programmes and national policies.
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The Dutch National Coordination Centre for Travellers' Health
Advice (Landelijk Coördinatiecentrum Reizigersadvisering, LCR) has
developed guidelines to optimally protect travellers living in the
Netherlands [3]. These guidelines are updated annually. However,
based on several survey studies, it is clear that about one third of Dutch
travellers are unaware of the risk of contracting infectious diseases.
When visiting countries in which these diseases are endemic [4,5].
Focusing on risk destinations that are relatively close to home for ex-
ample, such as Croatia, Turkey and Morocco, up to 64% of Dutch tra-
vellers are unaware of the recommended vaccinations [4]. Travellers
visiting friends and relatives (VFR) are particularly at risk, as they often
make the journey without getting pre-travel advice, then spend a longer
period of time abroad, often in close contact with the local inhabitants.
This puts them at greater risk of contracting infectious diseases [6,7].
Young travellers also constitute a signiﬁcant risk category, as many
parents assume that their children are suﬃciently protected by the
Nationwide Immunization Program (NIP). This includes the diphtheria,
tetanus and polio (DTP) vaccination, but not the other frequently re-
commended travel vaccinations, such as hepatitis A [8]. Given that
survey-only research is prone to contain bias, we studied adherence to
travel health guidelines adding serological data.
Serosurveillance data is widely available for NIP and some other
infectious diseases, but these data only reﬂect the immune status of the
general population [9]. Furthermore, plenty of data about speciﬁc
outbreaks is also available [10–12]. However, information about the
vaccination coverage in the healthy travelling populations, based on
seroprevalence of vaccine-preventable diseases (VPD), is limited. Prior
survey studies provide an indication of the frequency of pre-travel
consultations. However, this is not representative of the number of
unprotected travellers, as frequent travellers can be protected by vac-
cinations received in the past. The duration of protection oﬀered by
vaccines can range from a year to lifelong [3]. Besides, individuals who
were born in an endemic country or who have lived abroad for a certain
period could very well be protected by childhood vaccinations or nat-
ural infection, which means they would be in compliance with re-
commendations found in travel health guidelines when travelling to
certain destinations [13]. In other words, not visiting a travel clinic
prior to travel does not automatically mean that someone is travelling
unprotected. Moreover, travellers can sometimes forget that they have
received vaccinations [14] or vaccination records can be lost, all of
which means that data from survey-only studies can be unreliable.
Therefore, in carrying out the Dutch travel Vaccination Study (DiVeST)
our objective was to do unbiased research into: (1) the vaccination
status, and (2) the seroprotection rate of travelling families living in the
Netherlands. Given that we did not want to rely solely on vaccination
registration, because of potential loss of valuable information we
strived to increase the reliability of the vaccination status data by col-
lecting dry blood spots. This, so as to obtain insights in the presence of
antibodies. Given that all travellers between the ages of 12 and 16 at-
tend secondary school [15] it stands to reason that families travelling to
any destination, by any mode of transport and with any opinion about
the need to be vaccinated, can be reached via secondary schools. This
made these schools a highly suitable source of data for this study.
The hepatitis A virus (HAV) vaccination is a widely advised travel
vaccination - recommended according to the LCR guidelines in 184 out
of the 227 (81%) deﬁned destinations for which a vaccination is re-
commended [3]. Furthermore, the HAV vaccination is not included in
the Dutch NIP. Therefore, using HAV as a representative VPD, HAV
vaccination status and HAV seroprotection rates would provide valu-
able insights in the adherence to travel health guidelines in healthy
Dutch travelling families [16–18]. Within the context of DiVeST, it was
our intention to determine the proportion of Dutch travelling family
members that adhere to travel health guidelines and identify risk
groups among those that don't adhere. The overriding objective of all
this was to provide better advice to international travellers and oﬀer
protection to more of them.
2. Material and methods
2.1. Study population
This cross-sectional study was conducted in secondary schools
throughout the Netherlands between September 2016 and December
2018 Travellers, consisting of school personnel and students and their
family members who visited an Eastern European or non-European
country in the preceding year were recruited. Eastern Europe is in this
study deﬁned as Albania, Belarus, Bosnia and Herzegovina, Bulgaria,
Croatia, Cyprus, Czech, Estonia, Greece, Hungary, Kosovo, Latvia,
Lithuania, Macedonia, Moldova, Montenegro, Poland, Romania, Russia,
Serbia, Slovakia, Slovenia, Turkey, and Ukraine. To ensure we recruited
a suﬃcient number of travellers who should have been vaccinated ac-
cording to Dutch travel health guidelines, travellers to Western
European countries were excluded. Thirty-seven schools were ap-
proached, based on their respective locations (population density), type
of school (public or denominational) and education level. After re-
ceiving permission and conﬁrmation of participation in the study from
school principals, we visited the applicable schools on plenary evenings
or approached students’ families via e-mail. Once participants had
given written consent, anonymised demographic data, health data and
vaccination and travel history were collected with OpenClinica, an
electronic data-management application. Where available, copies of
vaccination records were obtained. Additionally, dried blood spots
were collected to ascertain vaccination status.
2.2. Sample collection
Following a ﬁnger prick (with a BD Lancet Device), capillary blood
was collected on ﬁlter paper cards (Whatman™ Protein Saver™ 903™),
dried for at least two hours and stored in foil bags with a small packet of
desiccant for a maximum of three weeks at room temperature.
Subsequently, these foil bags were placed in a freezer at minus 80°
Celsius until they could be tested.
2.3. Elution of DBS samples
The ﬁlter paper cards were thawed and dried blood spots (DBS)
were punched from these cards with a 12.7 mm or 6mm diameter
paper-hole punch. A 12.7mm diameter spot was considered to contain
26 μL of serum and a 6mm spot 5 μL. The spots were 1:6 eluted in
phosphate buﬀered saline (PBS) with 2% fetal bovine serum (FBS) and
incubated overnight on a rotating device in a room kept at 4° Celsius.
The next day the supernatant was transferred to a cone vial and the
paper spots were squeezed to get the maximum volume out of the DBS.
Eluates were centrifuged prior to testing.
2.4. Laboratory testing
Given that the standard clinical test for HAV serology is the anti-
HAV chemiluminescent immunoassay (CLIA), this test was used for the
ﬁrst screening of the eluates from all the DBS cards that were properly
ﬁlled. The test was performed following the instructions of the manu-
facturer (DiaSorin LIAISON®). The limit of detection of this assay is a
HAV antibody concentration of 18 micro international units per milli-
litre (mIU/ml), with a range of 15.5–21.5 mIU/ml. However, because of
the 1:6 dilution factor, we had to maintain a cut-oﬀ of 108 mIU/ml for
the CLIA of this study with a range of 93–129 mIU/ml.
Generally, used cut-oﬀs range from 10 to 33 mIU/ml [19,20], but it
is known that during the maintained protective periods of vaccines ti-
tres are much higher than the cut-oﬀsThe concentration of HAV anti-
bodies is at least 100 mIU/ml in 95% of the population in the ﬁrst six
months after primary vaccination, at least 1000 mIU/ml in 95% of the
population up to 15 years after secondary vaccination and 1000–10,000
mIU/ml up to nine years after natural infection [21–23].
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With a cut-oﬀ of 108 mIU/ml, the CLIA might not have been able to
detect all positive samples, especially the ones there longer than 6
months after primary vaccination. Therefore, we subsequently tested all
negative and equivocal eluates in the CLIA with a commercial enzyme-
linked immunosorbent assay (ELISA) (DiaSorin® ETI-AB-HAVK PLUS).
Also, because the CLIA needs an input volume of at least 240 μL per
sample, the eluates from DBS cards that were sparsely ﬁlled were tested
with the ELISA, as the input needed for this is only 50 μL. The ELISA
was carried out according to the instructions of the manufacture, with
additional dilutions of the calibrator. This resulted in a cut-oﬀ value of
10mIU/ml, leading to a cut-oﬀ of 60 mIU/ml due to the dilution factor.
Therefore, equivocal samples (values 20% from the cut-oﬀ) were also
considered positive (> 48 mIU/ml). Thus, we considered DBS eluates
negative if both the CLIA and ELISA gave a negative result, or if the
ELISA gave a negative result and the sample was not tested with the
CLIA. DBS eluates were considered positive if either the CLIA or the
ELISA gave a positive or an equivocal result. So, samples that were
tested negative or equivocal with the CLIA, but gave a positive or
equivocal result in the ELISA, were considered positive. This was be-
cause the cut-oﬀ of the ELISA was closer to the correlate of protection
(Supplemental Fig. 1).
2.5. Deﬁnitions
Travellers were categorised according to the pre-travel HAV vacci-
nation recommendation of the LCR as this would pertain to the (last)
trip they made to an Eastern European country or a country outside
Europe.
- PTA+ (pre-travel advice positive): travellers who visited a desti-
nation for which a pre-travel HAV vaccination is recommended.
- PTA- (pre-travel advice negative): travellers who visited a destina-
tion for which a pre-travel HAV vaccination is NOT recommended.
- PTA+/- (pre-travel advice depends): travellers who visited a des-
tination (South Africa or Israel) for which a pre-travel HAV vacci-
nation is only recommended under certain circumstances.
2.6. Data analysis
The study population was described using descriptive statistics.
Categorical variables were compared between categories with chi-
square tests and continuous variables with Mann-Whitney tests. The
following baseline variables were analysed: sex, age, education level,
nationality and immunocompromised state. Additionally, the following
travel characteristics and travel-related behaviour were also analysed:
destination, travel distance, length of stay and purpose of travel. Pre-
travel recommendations were compared with travel clinic visits, self-
reported HAV vaccination, vaccination records and serological status
with chi-square tests. Additionally, a logistic regression model was used
to calculate whether travel distance could predict vaccination status.
Data analyses were performed with IBM SPSS statistics 25 and RStudio.
95%- conﬁdence intervals were maintained and a p-value of< 0.05
was considered signiﬁcant.
2.7. Ethics
The study protocol was approved by the Medical Ethical Research
Committee of the Erasmus Medical Centre (MEC-2015-538).
Furthermore, the study was carried out in accordance with the de-
claration of Helsinki.
3. Results
Our study population consisted of 246 travellers from 188 families;
30% were children and 55% were females. The study participants were
mainly from municipalities in the Netherlands that were highly popu-
lated in 2015 [24]. A relatively large proportion of the study population
was highly educated with 49% of students attending VWO (the Dutch
equivalent of pre-university education) [25].
As shown in Table 1, 63% of travellers fell into category PTA+.
Their pre-travel advice would have included HAV vaccination, given
their destination and date of travel. Of these travellers, 9% went to
Croatia, where HAV vaccination was only recommended if they had
travelled before February 2017, due to a subsequent update of the LCR
guidelines. Furthermore, 7% of the study population were categorised
as PTA+/- because they travelled to South Africa or Israel, two coun-
tries for which the pre-travel advice only included the HAV vaccination
if travellers stayed under unhygienic circumstances. In category PTA-
there were 73 travellers, representing 30% of the study population.
Table 1 shows that the education level of both children and parents
diﬀers signiﬁcantly between the categories of travellers, with higher
education levels being more strongly represented in the PTA+ group.
Table 1
Travellers’ characteristics, categorised by pre-travel health advice.
PTA+ n = 155 (63%) PTA- n = 73 (30%) PTA+/- n = 17 (7%) Total n = 246° (100%) p-value
Sex 0.348
Female 36 (49.3) 90 (58.1) 11 (64.7) 137 (55.9)
Age (in years) 0.909
11–18 44 (28.4) 24 (32.9) 5 (29.4) 73 (29.8)
> 18-35 7 (4.5) 3 (4.1) 2 (11.8) 12 (4.9)
> 35-65 102 (65.8) 45 (61.6) 10 (58.8) 157 (64.1)
> 65 1 (0.6) 0 (0.0) 0 (0.0) 1 (0.4)
Education level (child)a 0.031
VMBO 28 (18.1) 17 (23.3) 0 (0.0) 45 (18.4)
HAVO 46 (29.7) 13 (17.8) 7 (41.2) 66 (26.9)
VWO 76 (49.0) 35 (47.9) 8 (47.1) 119 (48.6)
Highest level of education (parent)b 0.036
Secondary school 9 (8.2) 2 (4.2) 1 (8.3) 12 (7.1)
MBO 10 (9.1) 15 (31.9) 1 (8.3) 26 (15.4)
HBO 40 (36.4) 12 (25.5) 5 (41.7) 57 (33.7)
WO 46 (41.8) 18 (38.3) 5 (41.7) 69 (40.8)
Nationality 0.099
Other than Dutch or dual 16 (10.3) 4 (5.5) 0 (0.0) 20 (8.2)
Medical history 0.392
Immunocompromised 3 (1.9) 0 (0.0) 0 (0.0) 3 (1.2)
°For one participant the travel destination was not clear, so he could not be included in one of the PTA categories.
a VMBO stands for pre-vocational secondary education, HAVO stands for secondary general education and VWO stands for pre-university education level.
b MBO stands for senior secondary vocational education and training, HBO stands for higher professional education and WO stands for university level [44].
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P-values were comparable when PTA+/- travellers were excluded.
In Table 2, we compared the vaccination-related behaviour of the
three categories of travellers. As you would expect, more PTA+ than
PTA- travellers said they received pre-travel advice prior to their last
trip (36% as opposed to almost 3%). Similarly, according to their
vaccination records, more PTA+ than PTA- travellers were able to
prove they were protected against HAV (41% as opposed to 16%).
Despite the smaller numbers, according to their vaccination records,
PTA+/- travellers showed higher percentages than PTA+ travellers for
both receiving pre-travel advice and HAV protection. However, it must
be added here that many participants did not know their HAV vacci-
nation status (29% for PTA+/- and 97% for PTA-) and vaccination
records were often not available (34% for PTA+ and 48% for PTA-).
Therefore, we chose to compare compliance with guidelines of the
PTA+ group on the basis of the serological status of travellers. From
the 155 PTA+ travellers, 145 DBS eluates were available (Table 2). In
these samples, we found that 98 of the 145 (67%) had anti-HAV anti-
bodies (DBS+), compared to 22 of 66 (33%) in PTA- travellers and 8 of
16 (50%) of the PTA+/- travellers (p < 0.001).
Of the 47 PTA+ DBS- travellers, 35 (74%) had not visited a travel
clinic and 37 (79%) of them said that they were not aware that vacci-
nations were advised for their destination. Vaccination records of these
47 PTA+ DBS- individuals showed that 20 travellers (43%) indeed had
no proof that they were (still) protected against HAV, but according to
their vaccination records 9 travellers (19%) were HAV protected during
their trip. From the 18 cases in which DBS eluates were missing, 5
(28%) claimed to have been HAV vaccinated. In the PTA+ category
without DBS analysis, 2 out of 10 (20%) self-reported to be HAV vac-
cinated. Therefore, even in the most optimistic of scenarios, 23% of
PTA+ individuals travelled unprotected.
To distinguish the risk category of PTA+ travellers lacking anti-
HAV antibodies (DBS-), we compared baseline and travel characteristics
of DBS+ and DBS- travellers in this category (Table 3). Signiﬁcantly
more often children were DBS- than DBS+ (37% as opposed to nearly
23%, respectively). However, when using age as a continuous variable,
this signiﬁcant diﬀerence disappears. However, the proportion of
PTA+ children who were DBS- was 45% (17/38 available DBS). Fur-
thermore, the reason behind the journey for DBS- travellers was more
often than not to visit friends or relatives (VFR), as opposed to regular
holidays or business trips. Also, PTA+ DBS- individuals travelled to
closer destinations more frequently. A logistic regression model showed
that travel distance can be a signiﬁcantly predictor of serological status
(DBS+ or DBS-). PTA+ travellers who covered a distance of more than
5000 km (as the crow ﬂies) were more likely to be DBS+ than those
who travelled shorter distances to their destinations (OR = 2.89,
p = 0.00421). In 45% of cases, PTA+ DBS- participants travelled to
destinations in Eastern Europe or North Africa. Although we had to take
into account that the reported numbers are small, none of the travellers
to Eastern Europe and the Middle East sought advice from a pre-travel
clinic and neither did 86% of travellers to North Africa. Of the
PTA+ individuals travelling to these regions, 58, 50 and 33%, re-
spectively, were DBS- (Fig. 1).
4. Discussion and conclusion
According to the serological data from this study, only 67% of Dutch
travellers comply with travel health guidelines. Of all the travellers
visiting a region for which a HAV vaccination was recommended
(PTA+), only 36% received pre-travel advice prior to their trip, while
only 41% had proof of valid HAV vaccination in their records. In line
with these ﬁndings, in a third of all PTA+ instances, we could not ﬁnd
HAV antibodies in dry blood spot analyses, suggesting a lack vaccina-
tion protection. Non-adherence to travel health guidelines was asso-
ciated with being a child, visiting friends and relatives and/or only
travelling a short distance.
As expected, in the surveys that we conducted and in the records
that were available to us, there proved to be a relatively large amount
of missing vaccination data. Recall bias will have played a role here,
even though we tried to include travellers returning a maximum of one
year after their journey. We therefore increased the reliability of our
data by adding serological evidence of vaccination by analysing DBS
eluates.
The fact that 9 out of 47 PTA+ travellers who were DBS- could
show proof of being HAV protected during travel but had no detectable
antibodies, could be explained by the fact that their vaccination was up
to 32 weeks prior to travel and the DBS sampling was up to 12 months
after they returned. In other words, at the moment of DBS sampling
their HAV antibody concentrations could have decreased (probably
after the primary vaccination) and the vaccination was no longer valid,
although it would have oﬀered the necessary protection during their
journey. Also, the cut-oﬀ used in this study (48 mIU/ml) is slightly
higher than the commonly used correlates of protection (10–33 mIU/
ml). This could also explain this inconsistency, if the antibody titre
dropped just below our detection rate but was still above the correlate
of protection. Finally, people could belong to the small group (ap-
proximately 5%) of non- or low-responders to the HAV primary vacci-
nation [26,27].
Low adherence to travel health guidelines would seem to be mainly
a matter of unawareness of the vaccination recommendations [14],
particularly when it comes to travelling shorter distances. As destina-
tions in Eastern Europe seem relatively close to home, travellers prob-
ably underestimate the risk of contracting an infectious disease [28].
Together with Asia, Eastern Europe is the travel region where the most
morbidity attributable to vaccine-preventable diseases occurs [29].
However, the guidelines-compliance rate of travellers to Eastern Europe
was only 37% - while for these travellers HAV is one of the most pre-
ventable VPDs [29,30]. Asia is the most visited region among the Di-
VeST population and 82% of travellers who go there comply with travel
health guidelines. However, the number of people travelling to Turkey
and other countries quite close to the Netherlands but outside Europe,
such as Morocco and other North African countries, was relatively high.
This is probably due the number of VFR travellers going to those
countries. VFR travellers also seem to have a lower risk perception, as
do travellers who travel for holiday or business purposes [14]. How-
ever, it must be added here that VFR travellers face certain limitations
Table 2
HAV vaccination status compared with HAV vaccination pre-travel advice in guidelines.
Received pre-travel advice Self-reported HAV vaccination HAV protected according to vaccination
records
DBS eluate anti-HAV positivea TOTAL (%)
No (%) Yes (%) ? (%) No (%) Yes (%) ? (%) No (booklet) (%) Yes (%) ? (%) No (%) Yes (%) ? (%)
PTA+ 98 (63.2) 56 (36.1) 1 (0.7) 21 (13.5) 69 (44.5) 65 (41.9) 38 (24.5) 64 (41.3) 53 (34.2) 47 (30.3) 98 (63.2) 10 (6.5) 155 (100)
PTA- 69 (94.5) 2 (2.7) 2 (2.7) 1 (1.4) 1 (1.4) 71 (97.3) 26 (35.6) 12 (16.4) 35 (48.0) 44 (60.3) 22 (30.1) 7 (9.6) 73 (100)
PTA+/- 5 (41.7) 12 (70.6) 0 (0.0) 4 (23.5) 8 (47.1) 5 (29.4) 2 (11.8) 9 (52.9) 6 (35.3) 8 (47.1) 8 (47.1) 1 (5.9) 17 (100)
p-value <0.001 <0.001 0.002 < 0.001
a DBS eluate anti-HAV positive means a positive or equivocal result with the CLIA or ELISA. DBS eluate anti-HAV negative means a negative result with the CLIA
and ELISA, or a negative result with the ELISA and not tested on CLIA.
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when it comes to pre-travel precautions, such as the cost of consulta-
tions and vaccinations and a possible language barrier restricting their
access to travel health advice [31]. It could be argued that VFR tra-
vellers might be protected by natural immunity. However, in our study
population, anti-HAV seropositivity in VFR travellers was lower than in
non-VFR travellers.
Rates of non-compliance with travel health guidelines obtained
from the DiVeST were surprisingly consistent with the results of Dutch
survey-only studies. One third of travellers were unaware of the risks of
contracting infectious diseases while travelling to endemic regions
worldwide, while the same could be said for 64% of those travelling to
closer risk destinations [4,5]. Survey-only research from seven other
Western countries was also in line with our results, with 67% reporting
that they have been vaccinated. However, 70% of travellers sought pre-
travel advice, which was much higher than in our study population
[14]. Given that we had a relatively high rate of fully vaccinated people
(of all vaccination records showing any form of HAV vaccination, 80%
of them showed proof of having received the complete vaccination
Table 3
Characteristics of seronegative and seropositive PTA+ travellers.
PTA+ DBS- travellers (%)
n=47
PTA+ DBS+ travellers (%)
n=98
Total PTA+ travellers (%)
n=145
Chi-square p-value
Age groups (in years) 0.042
11–18 17 (37.0) 22 (22.5) 39 (27.1)
> 18-35 0 (0.0) 6 (6.1) 6 (4.2)
> 35-65 28 (60.9) 70 (71.4) 98 (68.1)
> 65 1 (2.2) 0 (0.0) 1 (0.7)
Education level (child)a 0.942
VMBO 8 (17.8) 20 (21.1) 28 (20.0)
HAVO 13 (28.9) 28 (29.5) 41 (29.3)
VWO 24 (53.3) 47 (49.5) 71 (50.7)
Duration of travel (in days) 0.488
0–7 10 (21.3) 12 (12.2) 22 (15.2)
> 7-28 33 (70.2) 76 (77.6) 109 (75.2)
> 28-56 4 (8.5) 9 (9.2) 13 (9.0)
> 56 0 (0.0) 1 (1.0) 1 (0.7)
Purpose of travel 0.011
Holiday 28 (60.9) 73 (74.5) 101 (70.1)
VFR 10 (21.7) 13 (13.3) 23 (16.0)
Business 4 (8.7) 12 (12.2) 16 (11.0)
Other 4 (8.7) 0 (0.0) 4 (2.8)
Destination 0.013
Eastern Europe 15 (31.9) 11 (11.2) 26 (17.9)
South/Central America 8 (17.0) 14 (14.3) 22 (15.2)
North Africa 6 (12.8) 12 (12.2) 18 (12.4)
Central Africa 4 (8.5) 11 (11.2) 15 (10.3)
Middle East 4 (8.5) 4 (4.1) 8 (5.5)
Asia 10 (21.3) 46 (46.9) 56 (38.6)
**Eastern Europe in this table includes the following PTA+ countries: Albania, Belarus, Bosnia, Bulgaria, Macedonia, Montenegro, Romania, Russia, Slovenia and
Turkey.
a VMBO stands for pre-vocational secondary education, HAVO stands for secondary general education and VWO stands for pre-university education level.
Fig. 1. Adherence to travel health guidelines per PTA+ region*
Missing data was excluded
Eastern Europe includes the following PTA+ countries: Albania, Belarus, Bosnia, Bulgaria, Macedonia, Montenegro, Romania, Russia, Slovenia and Turkey. South/
Central America includes Brazil, Colombia, Costa Rica, Cuba, Mexico, Nicaragua, Panama and Suriname. North Africa includes Egypt, Morocco, Gambia and Senegal.
Central Africa includes Ghana, Kenya, Mauritius, Namibia, Uganda and Tanzania. The Middle East includes Armenia, Georgia, UAE, Iran, Israel, Jordan and
Kazakhstan. Asia includes Cambodia, Hong Kong, India, Indonesia, Japan, Korea, Laos, Mongolia, Myanmar, Nepal, New Caledonia, Sri Lanka, Thailand and
Vietnam.
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series), it might be the case that our population comprised more ex-
perienced travellers [14]. A survey study from nine European airports,
reported a rate of non-compliance in travellers to developing countries
of at least 44% for HAV vaccination. This higher rate might be ex-
plained by a higher rate of VFR (22%) than in our study (16%) [32].
The HAV seroprevalence rate of 27% reported in the general Dutch
population aged 15–61, largely corresponds with the 30% seropositivity
in our PTA- group [33]. However, this pre-existing immunity also im-
plies that the seroprevalence rate of 67% in the PTA+ population might
be an overestimation of the adherence to travel health guidelines.
Children, VFR and short-distance travellers were mentioned as risk
groups before, among solo travellers and last-minute travellers [34–37].
These groups must be addressed with clear, bespoke information to
increase their adherence to travel health guidelines and thus decrease
travel-related morbidity [29]. Moreover, solutions must be found to
solve barriers faced by VFR travellers. In our opinion, awareness could
best be created via public channels shortly before the start of holiday
seasons and, to trigger the awareness of the relevant target groups,
speciﬁc (short-distance) destinations, travel purposes and age groups
should be mentioned [38,39]. The fact that adherence to travel health
guidelines in children is lower than in adults, can be related to in-
suﬃcient knowledge about the recommendations and availability of
preventive measures for these age groups or fear for side-eﬀects [36].
Some argue that in very young children hepatitis A is a very mild dis-
ease and therefore vaccination is not needed. However, Dutch travel
health guidelines recommend to vaccinate children older than 5 (all
participants in this study), because even if they are asymptomatic, they
will be infectious, putting naïve contacts at risk upon their return
[40,41].
While in this study we only focused on the vaccination status and
seroprevalence of HAV, it should only be seen as a representation of
adherence to guidelines. Travel health advice provided in guidelines is
not restricted to vaccination recommendations; it also includes re-
commendations regarding chemoprophylaxis and risk behaviour re-
lated to other travel-related aspects, such as food and water consump-
tion, sexual behaviour and protection against mosquito bites. An
extensive study by EuroTravNet has shown that pre-travel consultations
were associated with reduced morbidity when it comes to travel-related
infectious diseases [42]. The long-term protection aﬀorded by vacci-
nations can explain why travellers often do not visit a travel clinic prior
to their next trip. However, as travellers do not visit a travel clinic prior
to each journey, prevention other than vaccination, like pre-travel
health advices, hygiene and advice regarding risk behaviour, might also
be forgotten in the long run. Another point of attention is making
general healthcare providers aware of risks of travel-related infections
for travellers to destinations on short-distance, as short-distance tra-
vellers in particular are likely to consult their general practice instead
of a specialized travel clinic for pre-travel health advice [28,43].
Covering travellers from all over the Netherlands, including all
people who did and did not consult a travel clinic, the DiVeST re-
presents a broad travelling population. Although the study excluded
elderly and childless couples, it includes people who travelled with all
modes of transportation, in contrast with airport surveys. This is highly
relevant because air travel comprises only 57% of all international
travel [1]. Shorter-distance travellers are not only more likely to travel
by land, they are also more likely to be unvaccinated. In this study,
members of the same family were included, so as to recruit a larger
number of travellers. Although most participants were single-family
members, this might still have induced some selection bias. However,
the vaccination status of parents and children of the same family can
diﬀer, due to natural immunity and misperceptions of protection in-
duced by the NIP.
Furthermore, the study population had a greater proportion of
highly educated people than the general population. However, as there
is no signiﬁcant diﬀerence in education level between the PTA+ DBS-
and PTA+ DBS+ (Table 3), there is no reason to expect the adherence
rate to be diﬀerent. Seen in the context of all international travellers,
the study population comprised relatively few VFR travellers - 16% as
opposed to 27% of international travellers [1]. Furthermore, non-NIP
vaccinated individuals were less willing to participate and were thus
underrepresented. This implies that 67% adherence to travel health
guidelines is more likely to be an overestimation than an under-
estimation.
In conclusion it can be said that only two-thirds of Dutch travellers
adhere to travel health guidelines. Because their protection is sub-
optimal, during international travel children, VFR and short-distance
travellers are particularly vulnerable to contracting travel-related in-
fectious diseases like hepatitis A. According to our results, these sub-
groups constitute excellent target groups on which to focus in raising
the necessary awareness and thereby reducing travel-related morbidity.
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